Analyst Price Target is $21.00
▲ +377.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $21.00, with a high forecast of $33.00 and a low forecast of $9.00. The average price target represents a 377.27% upside from the last price of $4.40.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Immunome. This Buy consensus rating has held steady for over two years.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.